Related Experiment Video
Updated: May 10, 2025

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
Published on: August 21, 2017
Large vessel vasculitis associated with atezolizumab.
Prathyusha Chennupati1, Erika Pianin2, Neil Kramer3
1Division of Rheumatology, Department of Medicine, Overlook Medical Center, Summit, New Jersey, USA prathyusha.chennupati@atlantichealth.org Elliot.Rosenstein@atlantichealth.org.
Immune checkpoint inhibitors can cause rheumatological issues. This study details the first case of large vessel vasculitis solely linked to atezolizumab, which resolved after treatment discontinuation.
Area of Science:
- Oncology
- Rheumatology
- Immunology
Background:
- Immune checkpoint inhibitors (ICIs) are crucial cancer treatments.
- ICIs can trigger immune-related adverse events, including rheumatological conditions like vasculitis.
- Large vessel vasculitis (LVV) has been reported with some ICIs.
Purpose of the Study:
- To report the first case of LVV associated with atezolizumab monotherapy.
- To highlight the potential for atezolizumab to induce LVV.
Main Methods:
- Case report of a patient developing LVV.
- Clinical and radiographic assessment.
- Treatment with ICI discontinuation and glucocorticoids.
Main Results:
- The patient developed LVV during atezolizumab therapy.
- This is the first documented case of LVV solely due to atezolizumab.
- Treatment led to complete clinical and radiographic resolution.
Conclusions:
- Atezolizumab monotherapy can cause large vessel vasculitis.
- Discontinuation of atezolizumab and glucocorticoid therapy are effective treatments.
- Clinicians should consider LVV in patients on atezolizumab presenting with relevant symptoms.
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Vascular Spasm
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune...
Inflammatory Response I: Vascular and Cellular

